Page last updated: 2024-12-06

prostratin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Prostratin is a natural product isolated from the endemic Hawaiian plant *Homalanthus nutans*. It is a potent activator of protein kinase C (PKC) and has been shown to have a range of biological activities, including anti-cancer, anti-viral, and immunomodulatory effects. Its synthesis is complex and involves multiple steps, including a key Diels-Alder reaction. Prostratin is being investigated for its potential to treat HIV infection and cancer, as it has shown promising results in preclinical studies. Its unique mechanism of action, its ability to penetrate the blood-brain barrier, and its favorable safety profile make it an attractive candidate for drug development. While prostratin is not currently in clinical use, ongoing research is exploring its potential for treating a variety of diseases.'

prostratin: RN given refers to the (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64985
SCHEMBL ID15531877
MeSH IDM0193069

Synonyms (13)

Synonym
12-deoxyphorbol 13-acetate
prostratin
60857-08-1
nsc 623310
6h-cyclopropa(3,4)benz(1,2-e)azulen-6-one, 9a-(acetyloxy)-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-, (1ar,1bs,4ar,7as,7br,8r,9as)-
ccris 6292
ko94u6diq6 ,
6h-cyclopropa(3,4)benz(1,2-e)azulen-6-one, 9a-(acetyloxy)-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-, (1ar-(1aalpha,1bbeta,4abeta,7aalpha,8alpha,9aalpha))-
unii-ko94u6diq6
SCHEMBL15531877
mfcd00674138
DTXSID10893788
[(1r,2s,6r,10s,15r)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] acetate

Research Excerpts

Overview

Prostratin is a potent activator of protein kinases C (PKC), a family of related serine/threonine kinases that regulate many cellular processes. It is effective in the treatment of Human Immunodeficiency Virus (HIV) by acting as a latent HIV activator. Prostratin has potential as an inductive adjuvant therapy for highly active antiretroviral therapy (HAART)

ExcerptReferenceRelevance
"Prostratin is a preclinical candidate that induces HIV expression from latently infected CD4(+) T cells, potentially leading to their elimination through a virus-induced cytopathic effect or host anti-HIV immunity."( Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.
Beans, EJ; Chun, TW; Fournogerakis, D; Gauntlett, C; Heumann, LV; Kramer, R; Marsden, MD; Murray, D; Wender, PA; Zack, JA, 2013
)
1.38
"Prostratin is a potent activator of protein kinases C (PKC), a family of related serine/threonine kinases that regulate many cellular processes such as proliferation and apoptosis."( Protein kinases C as potential host targets for the inhibition of chikungunya virus replication.
Abdelnabi, R; Amrun, SN; Delang, L; Leyssen, P; Neyts, J; Ng, LF, 2017
)
1.18
"Prostratin is a protein kinase C activator and is effective in the treatment of Human Immunodeficiency Virus (HIV) by acting as a latent HIV activator."( De novo assembly of Euphorbia fischeriana root transcriptome identifies prostratin pathway related genes.
Barrero, RA; Bellgard, MI; Chapman, B; Keeble-Gagnère, G; Moolhuijzen, P; Qiu, D; Tang, Q; Yang, Y; Zhang, N, 2011
)
1.32
"Prostratin is a non-tumourogenic phorbol ester that delays HIV replication in vitro, but paradoxically activates HIV expression in latently infected cells."( Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes.
Alcamí, J; Beltán, M; Bermejo, M; Brown, SJ; García-Pérez, J; González, N; Hezareh, M; Rullas, J, 2004
)
2.49
"Prostratin is an unusual non-tumour promoting phorbol ester with potential as an inductive adjuvant therapy for highly active antiretroviral therapy (HAART) due to its ability to up-regulate viral expression from latent provirus. "( Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms.
Brown, SJ; Carpentier, JL; Cherix, N; Foti, M; Hezareh, M; Mouche, S; Moukil, MA; Pondarzewski, M; Szanto, I, 2004
)
2.01
"Prostratin is a unique phorbol ester that stimulates protein kinase C activity but is nontumor promoting. "( Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.
Boyd, MR; Culnan, DM; Dornadula, G; Kulkosky, J; Pomerantz, RJ; Roman, J; Schnell, M, 2001
)
3.2

Effects

Prostratin has been shown to reactivate latent HIV-1 and Tat-mediated transactivation may play an important role in this process.

ExcerptReferenceRelevance
"Prostratin has been proposed as a promising reagent for eradicating the latent HIV-1 provirus by inducing HIV-1 transcription activation. "( Protein kinase D3 is essential for prostratin-activated transcription of integrated HIV-1 provirus promoter via NF-κB signaling pathway.
Chen, R; Chen, Y; Ding, F; Hu, X; Liu, J; Liu, R; Peng, S; Wang, H; Wang, Y; Zhu, X; Zhu, Y, 2014
)
2.12
"Prostratin has been shown to reactivate latent HIV-1 and Tat-mediated transactivation may play an important role in this process."( Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells.
Rice, AP; Sung, TL, 2006
)
1.45

Compound-Compound Interactions

ExcerptReferenceRelevance
" We showed that protein kinase C agonists in combination with bromodomain inhibitor JQ1 or histone deacetylase inhibitors robustly induce HIV-1 transcription and virus production when directly compared with maximum reactivation by T cell activation."( Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
Bullen, CK; Durand, CM; Hill, AL; Laird, GM; Martin, AR; Rosenbloom, DI; Siliciano, JD; Siliciano, RF, 2015
)
0.42
" We found in this study that a novel PKC activator, 10-Methyl-aplog-1 (10MA-1), combined with an inhibitor of bromodomain and extra-terminal domain motifs, JQ1, strongly and synergistically reactivated latently infected HIV."( The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
Akari, H; Irie, K; Kikumori, M; Murata, M; Seki, Y; Tan, W; Tang, Y; Wardani, NP; Washizaki, A, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (13.92)18.2507
2000's21 (26.58)29.6817
2010's38 (48.10)24.3611
2020's9 (11.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.87 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index46.44 (26.88)
Search Engine Supply Index2.18 (0.95)

This Compound (32.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (6.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other74 (93.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]